Navigating Clinical Trials: Essential Knowledge for Dermatologists-Why Dermatologists Should be Involved in the Clinical Trials and Industry Relations

Why Dermatologists Should be Involved in the Clinical Trials and Industry Relations

Video Transcription

Video Summary

Dr. Mark Lebwal, Dean for Clinical Therapeutics at Mount Sinai, emphasizes the importance of dermatologists participating in clinical trials and collaborating with industry. His experience demonstrates how such involvement leads to better patient care with innovative treatments, boosts reputation, advances the dermatology field globally, and provides financial benefits. He illustrates with cases like using Vismodegib for metastatic basal cell carcinoma, highlighting the patient's long-term success. Clinical trials and resultant publications enhance credibility while aiding therapeutic advancements. Lebwal shares his journey with drugs like calcipotriene and infliximab, demonstrating successful off-label applications and combinations, which have profoundly impacted patient outcomes and dermatology practices. Encouraging opportunistic attitudes, Lebwal highlights that leveraging off-label uses of existing medications can significantly benefit careers and patient care, underscoring his own achievements as inspirational evidence.

Asset Subtitle

by Mark Lebwohl, MD, FAAD

Keywords

clinical trials

dermatology

new treatments

Mark Lebwell

patient care

dermatology advancements

off-label drug use

patient care innovation

Mark Lebwal